Design, synthesis, and pharmacological evaluation of benzamide derivatives as glucokinase activators

Add time:09/08/2019    Source:sciencedirect.com

A series of benzamide derivatives were assembled by using the privileged-fragment-merging (PFM) strategy and their SAR studies as glucokinase activators were described. Compounds 5 and 16b were identified having a suitable balance of potency and activation profile. They showed EC50 values of 28.3 and 44.8 nM, and activation folds of 2.4 and 2.2, respectively. However, both compounds displayed a minor reduction in plasma glucose levels on imprinting control region (ICR) mice. Unfavorable pharmacokinetic profiles (PK) were also observed on these two compounds.

We also recommend Trading Suppliers and Manufacturers of BenzaMide, 3-hydroxy-N,N-diMethyl- (cas 15789-03-4). Pls Click Website Link as below: cas 15789-03-4 suppliers

Prev:Synthesis and evaluation of 4-(2-pyrimidinylamino) benzamides inhibitors of hedgehog signaling pathway
Next:Research paperBenzamide derivatives and their constrained analogs as histamine H3 receptor antagonists)